Leavitt: Reforms Will Improve Oversight and Openness at FDA
Health and Human Services Secretary Mike Leavitt says drug safety reforms at the Food and Drug Administration will improve openness and oversight and will enhance the agency's independence. In keeping with this vision, the FDA will create a new independent Drug Safety Oversight Board to oversee the management of drug safety issues and will provide emerging information to doctors and patients about the risks and benefits of medicines.
"The public has spoken and they want more oversight and openness," Leavitt said during a Feb. 15, 2005, meeting at FDA headquarters in Rockville, Md. "They want to know what we know, what we do with the information, and why we do it. We will …
The rest of this article is only available to active members of Questia
Sign up now for a free, 1-day trial and receive full access to:
- Questia's entire collection
- Automatic bibliography creation
- More helpful research tools like notes, citations, and highlights
- Ad-free environment
Already a member? Log in now.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information:
Article title: Leavitt: Reforms Will Improve Oversight and Openness at FDA.
Contributors: Not available.
Magazine title: FDA Consumer.
Volume: 39.
Issue: 3
Publication date: May-June 2005.
Page number: 37.
© 1999 U.S. Government Printing Office.
COPYRIGHT 2005 Gale Group.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset